CAS No.8068-28-8,COLISTIN METHANESULFONATE SODIUM SALT Suppliers,MSDS download

Products Categories

Pharmaceutical (85)
Others (14)
Organic Chemicals (14)

Basic Information

Molecular Structure:
CAS No.:	8068-28-8
Name:	COLISTIN METHANESULFONATE SODIUM SALT

Formula:	C₅₈H₁₀₅N₁₆Na₅O₂₈S₅
Molecular Weight:	1749.82
Synonyms:	Colistinmethanesulfonicacid (6CI);Colimycin M;Colimycin sodium methanesulfonate;Colistimethate;Colistinsodium methanesulfonate;Colistin sulfomethate;Colistin sulfomethate sodium;Colistin, methyl sulfate, sodium salt;Colistinat;Coly-Mycin injectable;Colymycin M;Sodium colistimethate;Sodium colistinmethanesulfonate;W 1929;
EINECS:	232-516-9
Solubility:	Freely soluble in water
PSA:	0.00000
LogP:	0.00000

Total:96 Page 1 of 3 1 2 3 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 8068-28-8

Consensus Reports

SODIUM COLISTINEMETHANESULFONATE is reported in EPA TSCA Inventory.

Specification

The Colistimethate sodium, with the CAS registry number 8068-28-8, is also known as Colistinemethanesulfonate sodique. Its EINECS number is 232-516-9. This chemical's molecular formula is C₅₈H₁₀₅N₁₆Na₅O₂₈S₅ and molecular weight is 1749.82. What's more, its systematic name is Pentasodium [(4-{[3-(1-hydroxyethyl)-12,15-diisobutyl-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris{2-[(sulfonatomethyl)amino]ethyl}-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]amino}-3-{[3-hydroxy-2-({2-[ (6-methyloctanoyl)amino]-4-[(sulfonatomethyl)amino]butanoyl}amino)butanoyl]amino}-4-oxobutyl)amino]methanesulfonate. Its classification codes are: (1)Antibacterial; (2)Drug / Therapeutic Agent; (3)Human Data; (4)Reproductive Effect.

You can still convert the following datas into molecular structure:
(1)SMILES: [Na+].[Na+].[Na+].[Na+].[Na+].O=S([O-])(=O)CNCCC(NC(=O)CCCCC(C)CC)C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC1)C(O)C)CCNCS([O-])(=O)=O)CCNCS([O-])(=O)=O)CC(C)C)CC(C)C)CCNCS([O-])(=O)=O)CCNCS([O-])(=O)=O)C(O)C
(2)Std. InChI: InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
(3)Std. InChIKey: IQWHCHZFYPIVRV-UHFFFAOYSA-I

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	LDLo	intramuscular	90mg/kg/18H-I (90mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED	JAMA, Journal of the American Medical Association. Vol. 207, Pg. 2099, 1969.
guinea pig	LD50	intramuscular	444mg/kg (444mg/kg)		Oyo Yakuri. Pharmacometrics. Vol. 21, Pg. 737, 1981.
human	TDLo	intramuscular	56700ug/kg/9D (56.7mg/kg)	KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Annals of Internal Medicine. Vol. 66, Pg. 1052, 1967.
mouse	LD50	intramuscular	748mg/kg (748mg/kg)		Oyo Yakuri. Pharmacometrics. Vol. 21, Pg. 737, 1981.
mouse	LD50	intraperitoneal	126mg(base)/k (126mg/kg)		Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960.
mouse	LD50	intravenous	222mg(base)/k (222mg/kg)		Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960.
mouse	LD50	oral	> 767mg(base)/ (767mg/kg)		Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960.
mouse	LD50	subcutaneous	138mg(base)/k (138mg/kg)		Antibiotics Annual. Vol. 7, Pg. 41, 1959/1960.
rabbit	LD50	intramuscular	465mg/kg (465mg/kg)		Oyo Yakuri. Pharmacometrics. Vol. 21, Pg. 737, 1981.
rat	LD50	intramuscular	44mg/kg (44mg/kg)		Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
rat	LD50	intraperitoneal	86mg/kg (86mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)	Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 541, 1973.
rat	LD50	oral	5450mg/kg (5450mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)	Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 541, 1973.
rat	LD50	subcutaneous	87mg/kg (87mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)	Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 541, 1973.